Cancer Therapy
Liver-selective thyromimetic KAT-681 prevents liver tumors in rodent models
Published in Cancer Weekly, May 3rd, 2005
According to scientists in Japan, "we recently reported that short-term treatment with KAT-681 (KAT), a liver-selective thyromimetic, inhibits the development of preneoplastic lesions in rat livers and may be a candidate chemo-preventive agent for hepatocarcinogenesis."
"In this study, time-course observations of hepatocellular proliferative lesions were carried out during short-term and long-term treatment with KAT to investigate its anti-hepatocarcinogenic effects. The hepatocellular proliferative lesions in male F344 rats were induced by the initiation treatment of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-05-03)
More Articles from Cancer Weekly
- Breast Cancer
New treatment developed for BRCA1/2-associated disease - Carcinogenesis
Coal tar mixture activated carcinogenesis - Colorectal Cancer
Tumor formation and intestinal cell migration prevented by estrogens - Testicular Cancer
Transcriptional repression domain in N-terminal region of p53 identified - Abdominal Cancer
Large giant cell tumor of the sacrum excised via abdomino-sacral approach - Acute Myeloid Leukemia
Chemosensitivity index enables prediction of individual chemotherapy responses - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
